Evidence map›Paper›PMID 30351426›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).

Scott R Evans, Dean Follmann, Ying Liu, Thomas Holland, Sarah B Doernberg, Nadine Rouphael, Toshimitsu Hamasaki, Yunyun Jiang, Judith J Lok, Thuy Tien T Tran and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Review
  5. The Future Ain't What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  6. The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  7. Polymyxins: To Combine or Not to Combine?Antibiotics (Basel, Switzerland) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Scott R EvansThe Innovations in Design, Education, and Analysis Committee of the Biostatistics Center, George Washington Milken Institute School of Public Health.
Dean FollmannNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Ying LiuBiogen, Inc., Cambridge, Massachusetts.
Thomas HollandDuke University, Durham, North Carolina.
Sarah B DoernbergUniversity of California at San Francisco.
Nadine RouphaelEmory University, Atlanta, Georgia.
Toshimitsu HamasakiNational Cerebral and Cardiovascular Center, Japan.
Yunyun JiangThe Innovations in Design, Education, and Analysis Committee of the Biostatistics Center, George Washington Milken Institute School of Public Health.
Judith J LokBoston University, Massachusetts.
Thuy Tien T TranThe Innovations in Design, Education, and Analysis Committee of the Biostatistics Center, George Washington Milken Institute School of Public Health.
Anthony D HarrisUniversity of Maryland School of Medicine, Baltimore.
Vance G FowlerDuke University, Durham, North Carolina.
Helen BoucherTufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts.
Barry N KreiswirthNew Jersey Medical School-Rutgers University, Newark.
Robert A BonomoCase Western Reserve University, Cleveland, Ohio.
David Van DuinUniversity of North Carolina, Chapel Hill.
David L PatersonUniversity of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital Campus, Australia.
Henry ChambersUniversity of California at San Francisco.

Funding

Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863NIAID NIH HHS UM1 AI104681
6 · The paper itself

Abstract

Patient management is not based on a single decision. Rather, it is dynamic: based on a sequence of decisions, with therapeutic adjustments made over time. Adjustments are personalized: tailored to individual patients as new information becomes available. However, strategies allowing for such adjustments are infrequently studied. Traditional antibiotic trials are often nonpragmatic, comparing drugs for definitive therapy when drug susceptibilities are known. COMparing Personalized Antibiotic StrategieS (COMPASS) is a trial design that compares strategies consistent with clinical practice. Strategies are decision rules that guide empiric and definitive therapy decisions. Sequential, multiple-assignment, randomized (SMART) COMPASS allows evaluation when there are multiple, definitive therapy options. SMART COMPASS is pragmatic, mirroring clinical, antibiotic-treatment decision-making and addressing the most relevant issue for treating patients: identification of the patient-management strategy that optimizes the ultimate patient outcomes. SMART COMPASS is valuable in the setting of antibiotic resistance, when therapeutic adjustments may be necessary due to resistance.

Indexed as

Disease ManagementRandomized Controlled Trials as TopicAnti-Bacterial AgentsClinical Decision-MakingHumansPrecision MedicineResearch DesignAnti-Bacterial Agentspragmatic trialsequential randomizationstrategy

Identifiers

PMID30351426
PMCPMC6522685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.